You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 30, 2025

CLINICAL TRIALS PROFILE FOR FLORTAUCIPIR F-18


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Flortaucipir F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01992380 ↗ A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects Completed Avid Radiopharmaceuticals Phase 1 2013-11-13 This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers, MCI and AD subjects provide the same results.
NCT02016560 ↗ Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects Completed Avid Radiopharmaceuticals Phase 2/Phase 3 2013-12-01 A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
NCT02051764 ↗ Imaging Characteristics of a Follow-up 18F-AV-1451 Scan Terminated Avid Radiopharmaceuticals Phase 2 2014-05-01 This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
NCT02079766 ↗ 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy Completed Avid Radiopharmaceuticals Phase 2 2014-06-01 This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
NCT02167594 ↗ Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Completed Avid Radiopharmaceuticals Phase 1 2014-08-12 This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Flortaucipir F-18

Condition Name

Condition Name for Flortaucipir F-18
Intervention Trials
Alzheimer's Disease 9
Alzheimer Disease 8
Cognitive Decline 2
Mild Cognitive Impairment 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Flortaucipir F-18
Intervention Trials
Alzheimer Disease 17
Dementia 3
Cognitive Dysfunction 3
Brain Injuries, Traumatic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Flortaucipir F-18

Trials by Country

Trials by Country for Flortaucipir F-18
Location Trials
United States 76
Australia 3
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Flortaucipir F-18
Location Trials
California 11
Pennsylvania 8
Massachusetts 6
Texas 5
Rhode Island 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Flortaucipir F-18

Clinical Trial Phase

Clinical Trial Phase for Flortaucipir F-18
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Flortaucipir F-18
Clinical Trial Phase Trials
Completed 16
Terminated 2
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Flortaucipir F-18

Sponsor Name

Sponsor Name for Flortaucipir F-18
Sponsor Trials
Avid Radiopharmaceuticals 18
The Cleveland Clinic 1
Neil M Rofsky, MD, MHA 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Flortaucipir F-18
Sponsor Trials
Industry 19
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

FLORTAUCIPIR F-18: A Breakthrough in Alzheimer's Disease Diagnosis

Introduction

Flortaucipir F-18, marketed under the name TAUVID™, is a groundbreaking diagnostic agent approved by the U.S. FDA for the detection of aggregated tau neurofibrillary tangles (NFTs) in the brains of patients suspected of having Alzheimer's disease. This article delves into the clinical trials, market analysis, and future projections for this innovative drug.

Clinical Trials Overview

Trial Design and Participants

The FDA approval of TAUVID was based on evidence from 19 clinical trials involving 1921 patients across 322 sites in several countries, including the United States, Australia, Belgium, Canada, France, Japan, Netherlands, and Poland[4].

  • Trial 1 and Trial 2: These trials were pivotal in establishing the efficacy of TAUVID. In Trial 1, PET scan images of terminally ill patients were compared with brain autopsy findings to validate the accuracy of TAUVID in detecting NFTs. Trial 2 extended this by including additional patients with suspected Alzheimer's disease and evaluating inter-reader agreement among different readers[4].

Key Findings

  • Sensitivity and Specificity: The Phase 3 study demonstrated that flortaucipir F-18 met its primary endpoints, showing statistically significant sensitivity and specificity for detecting tau pathology and predicting Alzheimer's disease diagnosis[3].
  • Inter-reader Agreement: The trials showed high inter-reader agreement, indicating that the readings were consistent among different readers, which is crucial for reliable diagnostic outcomes[4][5].

Safety Profile

  • The safety of TAUVID was evaluated in 19 trials, with the most common adverse reactions reported being headache (1.4%), injection site pain (1.2%), and increased blood pressure[1][4].
  • Treatment-emergent adverse events (TEAEs) were monitored up to 48 hours after injection, with most events being mild and transient[5].

Mechanism of Action and Pharmacokinetics

How It Works

Flortaucipir F-18 is a small lipophilic tracer that contains the radioactive isotope [18F]fluoride. It crosses the blood-brain barrier and binds to aggregated tau protein, a hallmark of Alzheimer's disease. The radioactive decay of [18F]fluoride emits gamma photons that are detectable by PET imaging, allowing for the visualization of NFTs in the brain[2].

Pharmacokinetic Profile

  • Absorption and Distribution: After intravenous administration, flortaucipir F-18 quickly passes through systemic circulation and crosses the blood-brain barrier, with peak brain uptake achieved within minutes. Equilibrium is reached approximately 80-100 minutes after administration[2][5].

Market Analysis

Market Need

Alzheimer's disease is a significant global health issue, with millions of people affected worldwide. The current diagnostic tools often rely on clinical symptoms and biomarkers like beta-amyloid plaques, but the ability to directly image tau NFTs fills a critical gap in diagnostic capabilities.

Competitive Landscape

TAUVID is the first and only FDA-approved diagnostic agent for imaging tau NFTs, giving it a unique position in the market. Other diagnostic agents, such as those targeting beta-amyloid, do not provide the same level of specificity for tau pathology[1][2].

Market Potential

The approval of TAUVID opens up new avenues for early and accurate diagnosis of Alzheimer's disease, which can significantly impact patient care and treatment planning. The market potential is substantial, given the growing need for precise diagnostic tools in neurology.

Future Projections

Expanding Indications

While TAUVID is currently indicated for Alzheimer's disease, ongoing research may explore its use in other tauopathies. However, it is important to note that TAUVID is not indicated for the detection of chronic traumatic encephalopathy (CTE) due to differences in tau conformation and distribution[1][2].

Technological Advancements

Advancements in PET imaging technology and the development of more sensitive tracers could further enhance the diagnostic capabilities of TAUVID. Integration with other diagnostic modalities, such as MRI and CSF biomarkers, may also improve diagnostic accuracy.

Regulatory and Reimbursement Landscape

The FDA approval of TAUVID sets a precedent for future regulatory pathways for similar diagnostic agents. Reimbursement policies will be crucial in making this diagnostic tool accessible to a broader patient population.

Key Takeaways

  • First FDA-Approved Tau Imaging Agent: TAUVID is the first diagnostic agent approved for imaging aggregated tau NFTs in the brain.
  • Clinical Trial Success: Phase 3 trials demonstrated high sensitivity and specificity for detecting tau pathology.
  • Safety Profile: Common adverse reactions are mild and transient.
  • Market Potential: Significant market potential due to the growing need for accurate Alzheimer's disease diagnosis.
  • Future Directions: Potential for expanding indications and technological advancements.

FAQs

What is flortaucipir F-18 used for?

Flortaucipir F-18, marketed as TAUVID, is used for the PET imaging of aggregated tau neurofibrillary tangles in adult patients being evaluated for Alzheimer's disease[2].

How does flortaucipir F-18 work?

It crosses the blood-brain barrier and binds to aggregated tau protein, emitting gamma photons detectable by PET imaging, allowing for the visualization of NFTs in the brain[2].

What were the key findings of the clinical trials?

The trials showed high sensitivity and specificity for detecting tau pathology and predicting Alzheimer's disease diagnosis, with good inter-reader agreement among different readers[3][4].

What are the common adverse reactions associated with TAUVID?

The most common adverse reactions reported were headache, injection site pain, and increased blood pressure[1][4].

Is TAUVID indicated for chronic traumatic encephalopathy (CTE)?

No, TAUVID is not indicated for the detection of CTE due to differences in tau conformation and distribution[1][2].

Sources

  1. Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease. Investor.lilly.com.
  2. Flortaucipir F-18: Uses, Interactions, Mechanism of Action - DrugBank. Go.drugbank.com.
  3. Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent. Prnewswire.com.
  4. Drug Trial Snapshot: TAUVID - FDA. Fda.gov.
  5. Positron Emission Tomography Imaging With [18F]flortaucipir and Alzheimer Disease. Jamanetwork.com.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.